News and Trends 7 Jul 2022 French Juvisé buys gastro product in €400M finance deal French pharmaceutical company, Juvisé has just bought worldwide commercial rights to Pylera from US biopharmaceutical company Abbvie. Juvisé negotiated financing of €400 million ($408 million) with Société Générale as part of the deal and also the refinancing of its existing debt. Pylera is an antimicrobial tri-therapy that helps gastro-intestinal Helicobacter pylori infections. Lazard and Latham […] July 7, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jun 2020 AbbVie and Genmab Strike €3.4B Immuno-Oncology Megadeal AbbVie and Genmab have announced a €3.4B collaboration deal that ranks as the second biggest strategic alliance in European biotech in 2020. The partners aim to commercialize three phase I-stage antibody drugs for undisclosed types of solid and liquid cancer. Upfront, the US AbbVie will pay the Danish biotech €659M, with up to €2.77B available […] June 11, 2020 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
More News! 16 Nov 2018 AbbVie Enters Industry Collaboration to Fight Alzheimer’s and Parkinson’s Disease The UK biotech Mission Therapeutics has teamed up with AbbVie to develop new drugs to treat the neurodegenerative conditions Alzheimer’s disease and Parkinson’s disease. The new collaboration aims to fund the preclinical development of drugs that inhibit proteins called deubiquitinating enzymes. Deubiquitinating enzymes modify proteins in the cell, controlling essential functions such as what the […] November 16, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2017 French Biotech Lures Big Pharma with Fibrosis Treatments This week, Inventiva has received a milestone payment from Boehringer Ingelheim and extended its collaboration with AbbVie. Today, Boehringer Ingelheim has decided today to take the next step forward and start development of the first candidate against idiopathic pulmonary fibrosis (IPF) from a research partnership with Inventiva. This has triggered a €2.5M payment for the French biotech, which is […] September 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2017 Next-Gen Cancer Antibody Technology from Germany enters the Clinic Apogenix’ partner AbbVie has started the first clinical trial for an immuno-oncology candidate with the potential to outperform antibody therapy. The German biotech Apogenix has announced that its partner AbbVie has initiated a Phase I trial testing its next-generation immuno-oncology technology in patients suffering from solid tumors, non-Hodgkin’s lymphoma (NHL) and acute myeloid leukemia (AML). The candidate […] April 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2017 Galapagos Enters Clinical Trials with New Cystic Fibrosis Drug Galapagos has announced to kick off a Phase I trial with its novel Cystic Fibrosis potentiator GLPG3067, triggering a €7M milestone payment from AbbVie. Galapagos and AbbVie teamed up in 2013, with the aim of developing a triple combination therapy for the treatment of Cystic Fibrosis (CF). Now, Galapagos announced the start of a Phase […] March 23, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 2 Feb 2017 Galapagos kicks off a Phase IIa trial for Cystic Fibrosis After Galapagos and AbbVie expanded their collaboration on cystic fibrosis, Galapagos now announces the start of their Phase IIa trial for a novel cystic fibrosis corrector. Since entering their collaboration with AbbVie on cystic fibrosis (CF) in 2013, Galapagos has received almost €40M in milestone payments from AbbVie. Galapagos now announced the start of a Phase […] February 2, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 29 Nov 2016 One Step Closer to the First Triple Combination Therapy for Cystic Fibrosis Galapagos and AbbVie are closer to launching a cystic fibrosis treatment that can outperform the current standards. However, gene therapy and CRISPR might end up taking over in the long term. Despite being abandoned by AbbVie in its rheumatoid arthritis program, Galapagos and the big US pharma expanded their cystic fibrosis partnership in May. The […] November 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2016 UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug Sanofi and Regeneron (NY, US) have ruled their phase III clinical trial immunotherapy Sarilumab a huge success. Now awaiting US FDA and EMA approval, the results from the latest study were presented at the American College of Rheumatology (ACR) annual meeting in San Francisco. Should Sarilumab be approved, this immunotherapy will be used to treat […] October 31, 2016 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2016 New Psoriasis Antibody Therapy puts pressure on Best-Seller drug Humira New results from a Phase III trial show that guselkumab, an antibody therapy for the autoimmune disease plaque psoriasis, is performing better than the number one best-seller drug Humira (adalimumab) from AbbVie. The new drug is expected to be commercially available as early as 2018. Since MorphoSys licensed guselkumab to Janssen Biotech, in 2007, the drug has been performing […] October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email